RxDoctor Payments Data

Sheldon Fayner, MD

Family Medicine · Anaheim, CANPI 1770758310

Payments from drug & device makers

$2,727in general payments, 2019–2025

Across 119 payments — averaging $22.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$711
  • Pfizer$635
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$237
  • AbbVie$220
  • Merck$216
  • Lilly USA, LLC$182
  • plus $526 from 10 others

What the payments were for

  • Food & beverage$2,727100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,727 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$42,948
Medicare patients
67
Services billed
406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$51,619
XareltoRivaroxaban11$19,176
EliquisApixaban28$18,995
JardianceEmpagliflozin18$18,046
FarxigaDapagliflozin Propanediol18$15,316
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,085
Repatha SureclickEvolocumab11$6,079
DapagliflozinDapagliflozin Propanediol13$5,673
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen242$4,703
Arnuity ElliptaFluticasone Furoate13$3,814
Albuterol Sulfate HfaAlbuterol Sulfate106$2,805
Varenicline Tartrate14$2,393
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,079
Oxycodone Hcl46$1,722
Atorvastatin Calcium194$1,597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$711$51,61947 claims
Johnson & JohnsonXarelto$136$19,17611 claims
PfizerEliquis$635$18,99528 claims
Boehringer IngelheimJardiance$15$18,04618 claims
AstraZenecaFarxiga$49$15,31618 claims
GSKTrelegy Ellipta, Arnuity Ellipta$15$13,89924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →